NASOPHARYNGEAL CANCINOMA (NPC)

This study is testing if a shorter treatment schedule with the immunotherapy drug tislelizumab, combined with standard chemotherapy and radiation, works as well as the standard, longer schedule for people with advanced nasopharyngeal cancer. It will involve about 418 adults to se…

This study is testing whether adding the drug anlotinib to the current standard treatment (immunotherapy plus chemotherapy and radiation) works better for people with high-risk, locally advanced nasopharyngeal cancer. It will enroll 412 adults to compare the two treatment approac…

This study is testing a new two-drug combination as the first treatment for people with advanced nasopharyngeal cancer that has come back or spread. It aims to see if the drugs Becotatug Vedotin and Pucotenlimab are safe and effective at controlling the cancer. The trial will enr…

This study is testing a new treatment plan for people whose nasopharyngeal (upper throat) cancer has come back only in the original area. Patients first receive a combination of immunotherapy (pembrolizumab) and chemotherapy to shrink the tumor. Doctors then surgically remove any…

This study is testing a new drug called becotatug vedotin for people with advanced nasopharyngeal cancer (a type of throat cancer) whose cancer doesn't shrink enough after initial chemo-immunotherapy. The goal is to see if adding this drug during radiation and follow-up treatment…

This large Phase 3 trial is testing if adding an oral chemotherapy drug (capecitabine) to a standard immunotherapy drug (adebrelimab) works better to control cancer after initial treatment. It's for patients with advanced nasopharyngeal cancer who still have signs of the Epstein-…

This study is testing whether adding a special low-dose radiation to a standard chemotherapy and immunotherapy combination can better control advanced nasopharyngeal cancer that has returned or spread. It will involve about 55 adults with this specific type of head and neck cance…